Ductal-dependent congenital heart diseaseMANAGEMENT

PEDIATRIC-SPECIFIC PRESENTATIONS · 12 SECTIONS

⚲

485 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Bronchiolitis Croup Ductal-dependent congenital heart disease Emergency delivery Febrile seizure Hypercyanotic (tet) spell Inborn error of metabolism Intussusception Kawasaki disease Necrotizing enterocolitis Neonatal jaundice Neonatal resuscitation Nursemaid's elbow Pediatric DKA and cerebral edema Pediatric fever 0 to 28 days Pediatric fever 29 to 60 days Pediatric fever 61 to 90 days Pediatric septic shock Pyloric stenosis

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp73

Immediate recognition and stabilization

›High-risk presentation triggers

›Collapsed, grey, or shock-appearing neonate in the first two weeks of life

›Poor feeding, lethargy, mottling

›Weak cry, diaphoresis with feeds

›Profound cyanosis unresponsive to supplemental oxygen

›SpO2 that fails to rise above 85-90% on 100% FiO2

›Absent or markedly diminished femoral pulses

›Four-limb pulse and blood pressure discrepancy

›New murmur, gallop, or hepatomegaly in a neonate in shock

›Age under 1 month with any of the above; ductal closure typically occurs day 3 to day 14

›Rare later presentation to 4-6 weeks with a slow-closing or restrictive ductus

›Suspicion is the trigger, not confirmation

›Start prostaglandin E1 on clinical suspicion of ductal-dependent disease

›Do not wait for echocardiography to confirm the diagnosis before starting

›Do not wait for sepsis workup results to return before starting

›A normal newborn pulse oximetry screen does not exclude ductal-dependent disease

›Screening is commonly passed with the lesion still present

›Treat as cardiac until proven otherwise in any afebrile or febrile neonatal shock

PGE1 initiation and airway plan

›Alprostadil (prostaglandin E1) infusion

›Initiate 0.05-0.1 mcg/kg/min IV continuous infusion

›Verify against current pediatric guideline before use

›Reassess for response (improved saturation or improved perfusion and pulses) within 15-30 minutes

›If effective, wean to lowest effective maintenance dose, commonly 0.01-0.05 mcg/kg/min

›Verify against current pediatric guideline before use

›Maximum practical dose 0.4 mcg/kg/min; doses above this rarely add benefit and increase adverse effects

›Verify against current pediatric guideline before use

›Route and access

›Continuous infusion only; no bolus dosing

›Dedicated reliable line, umbilical venous catheter preferred if available

›Never interrupt the infusion for transport, line change, or procedure without an immediate replacement running

›Rebound ductal constriction can occur within minutes of interruption

›Predictable adverse effects

›Apnea in roughly 10-12% of neonates, most often within the first 6 hours of infusion

›Risk highest in neonates under 2 kg and at higher infusion doses

›Fever

›Cutaneous flushing from vasodilation

›Systemic hypotension

›Jitteriness or seizure-like activity

›Hypoglycemia

›With prolonged use beyond several days: gastric outlet obstruction from antral hyperplasia, long-bone cortical hyperostosis, thrombocytopenia

›Airway plan that must accompany PGE1

›Continuous cardiorespiratory and apnea monitoring from the first dose

›Airway equipment and a clinician capable of emergent intubation at the bedside before starting the infusion

›Elective intubation before interfacility transport

›Strongly consider for any dose above 0.05 mcg/kg/min or for transport time over 30-60 minutes

›Do not rely on being able to intubate emergently mid-transport

›Do not delay PGE1 initiation to arrange intubation first

›Start the infusion, secure the airway proactively rather than reactively

Hemodynamic and saturation targets

›Saturation and oxygen targets

›Target SpO2 75-85% in most ductal-dependent single-ventricle or mixing physiology

›Do not target maximal or normal saturation

›Higher targets acceptable once surgical or catheter palliation restores balanced circulation

›Avoid high-concentration or 100% supplemental oxygen empirically

›Oxygen is a potent ductal constrictor and lowers pulmonary vascular resistance

›In parallel-circulation physiology this shifts flow toward the lungs and away from the body

›Room air or blended low-flow oxygen preferred while cardiac lesion is undifferentiated

›Perfusion and pressure targets

›Mean arterial pressure and capillary refill as primary perfusion markers rather than SpO2 alone

›Preserve rather than maximize systemic perfusion pressure

›Excess afterload reduction can worsen an already duct-dependent systemic circulation

›Reassess perfusion after every intervention (fluid, oxygen change, pressor change)

Key decision points and escalation triggers

›Escalation triggers

›No improvement in perfusion or saturation within 15-30 minutes of PGE1 initiation

›Check line patency and infusion delivery first; infiltrated or occluded lines are the most common cause of apparent PGE1 failure

›If line is confirmed patent and dose is adequate, escalate to pediatric cardiology and consider mixing-lesion physiology needing atrial septostomy

›Apnea or desaturation after PGE1 start

›Proceed to intubation rather than increasing oxygen concentration

›Cardiac arrest or refractory shock despite PGE1 and inotropic support

›Consider extracorporeal membrane oxygenation as a bridge to definitive repair

›Consult and activation triggers

›Emergent pediatric cardiology consultation on suspicion, not after confirmation

›Neonatology or pediatric critical care co-management from arrival

›Pediatric cardiac surgery notification if a duct-dependent lesion is confirmed or strongly suspected

02History/hx33

Presenting symptoms by age

›Neonatal shock and collapse presentation (systemic flow lesions)

›Poor feeding and increasing lethargy over hours

›Grey or mottled color noted by caregivers

›Rapid or grunting breathing

›Decreased urine output or fewer wet diapers

›Timing typically day 3 to day 14 of life as the ductus closes

›Neonatal cyanosis presentation (pulmonary flow and mixing lesions)

›Blue or dusky color of lips, tongue, or extremities noted at rest or with crying

›Cyanosis that does not improve with supplemental oxygen at home or in transport

›Episodic worsening with feeding or crying (hypercyanotic spell physiology)

›Symptom timeline relative to discharge

›Well-appearing at newborn discharge, deterioration in the days that follow

›Passed newborn pulse oximetry screening; this does not exclude the diagnosis

Perinatal and prenatal history

›Prenatal detection

›Fetal anomaly ultrasound findings

›Fetal echocardiogram result if performed

›Known lesion allows planned delivery at a cardiac center; unrecognized lesion is far more common in ED presentations

›Delivery and neonatal course

›Gestational age and birth weight

›Apgar scores and resuscitation at delivery

›Nursery course and any murmur documented before discharge

›Newborn pulse oximetry screening result and timing

Risk factors and family history

›Maternal and pregnancy risk factors

›Maternal diabetes (associated with transposition of the great arteries and other structural disease)

›Maternal rubella, lupus, or teratogen exposure

03Physical Exam/exam46

Vital signs and four-limb assessment

›Four-limb blood pressure

›Obtain blood pressure in both arms and both legs

›Right arm represents pre-ductal circulation

›Legs represent post-ductal circulation

›Upper-to-lower extremity systolic gradient greater than 10-20 mmHg, or unobtainable lower extremity pressure

›Suggests coarctation of the aorta or interrupted aortic arch

›Gradient may be absent while the ductus remains open; recheck as the duct closes

›Pre-ductal and post-ductal oxygen saturation

›Right hand (pre-ductal) and either foot (post-ductal) SpO2

›Differential greater than 3% suggests right-to-left ductal shunting

›Present in both ductal-dependent systemic flow lesions and persistent pulmonary hypertension of the newborn

›Reverse differential (post-ductal higher than pre-ductal)

›Suggests transposition physiology with a pulmonary-to-systemic shunt pattern

›Heart rate and respiratory rate by age

›Neonatal tachycardia above 160-180 beats per minute at rest

›Neonatal tachypnea above 60 breaths per minute

›Bradycardia in a decompensating neonate is a pre-terminal finding

Perfusion and pulse exam

›Femoral and peripheral pulse character

›Weak, thready, or absent femoral pulses

›Compare directly with brachial pulses at the same time

›Classic for coarctation, interrupted aortic arch, critical aortic stenosis, hypoplastic left heart syndrome

›Bounding pulses with wide pulse pressure

›Consider large left-to-right shunt or patent ductus with runoff, or truncus arteriosus

›Capillary refill and skin findings

›Capillary refill time greater than 3 seconds

›Mottling, grey color, cool extremities

04Differential Diagnosis/ddx29

Ductal-dependent pulmonary blood flow (profound cyanosis group)

›Right-sided obstructive and mixing lesions

›Pulmonary atresia with intact ventricular septum

›Pulmonary atresia with ventricular septal defect

›Critical pulmonary valve stenosis

›Tricuspid atresia

›Severe tetralogy of Fallot with critical right ventricular outflow obstruction

›Severe Ebstein anomaly with functional pulmonary atresia

›Transposition of the great arteries

›Ductal-dependent for intercirculatory mixing rather than pulmonary blood flow directly

›Managed with the same PGE1-first approach and shares the profound-cyanosis presentation

Ductal-dependent systemic blood flow (shock group)

›Left-sided obstructive lesions

›Hypoplastic left heart syndrome

›Critical aortic stenosis

›Coarctation of the aorta (severe or critical)

›Interrupted aortic arch

›Shone complex with critical inflow or outflow obstruction

Non-cardiac mimics presenting as shock or cyanosis

›Sepsis mimic

›Neonatal bacterial sepsis with poor perfusion, hypotension, respiratory distress

›Clinically indistinguishable from duct-dependent systemic shock at first presentation

›Both are treated simultaneously; neither diagnosis is excluded by starting therapy for the other

›Metabolic and other mimics

›Inborn error of metabolism with acute decompensation

›Congenital adrenal hyperplasia with salt-wasting crisis

›Severe anemia or hyperviscosity

›Pulmonary and CNS mimics of cyanosis

05Laboratory Tests/lt37

Core labs and interpretation

›Blood gas

›Arterial or capillary blood gas

›Metabolic acidosis from tissue hypoperfusion

›pH and base deficit trend with resuscitation

›Lactate

›Elevated lactate reflects hypoperfusion, not specific to sepsis or cardiac cause

›Trend, not a single value, guides response to therapy

›Glucose

›Point-of-care glucose on every lethargic, shocked, or poorly feeding neonate

›Hypoglycemia is common in neonatal shock of any cause and worsens outcome if missed

›Dextrose 10% 2 mL/kg IV for confirmed neonatal hypoglycemia

›Verify against current pediatric guideline before use

›Electrolytes and renal function

›Sodium, potassium, calcium

›Hypocalcemia in 22q11.2-associated lesions (interrupted aortic arch, truncus arteriosus)

›Hyperkalemia in congenital adrenal hyperplasia mimic

›Creatinine for shock-related renal injury

›Cardiac-directed labs

›Hyperoxia test

›Obtain a right radial (pre-ductal) arterial blood gas on 100% FiO2 for approximately 10 minutes

›PaO2 remaining below 100 mmHg suggests fixed intracardiac right-to-left shunting (cyanotic CHD)

›PaO2 rising above 150-200 mmHg suggests pulmonary parenchymal disease rather than fixed cardiac shunting

›Hyperoxia test limitations

›Does not reliably distinguish cyanotic CHD from persistent pulmonary hypertension of the newborn; both can fail to rise

›A positive test supports urgent echocardiography; it does not replace it and should not delay PGE1

›Troponin and BNP or NT-proBNP

›Elevated in significant ventricular strain or dysfunction

06Diagnostic Tests/dt32

Scoring Systems

›Newborn pulse oximetry screening algorithm

›Standard protocol

›Right hand (pre-ductal) and one foot (post-ductal) SpO2 at 24-48 hours of age

›Pass, fail, or retest thresholds per the AAP/AHA algorithm

›Screening can be passed with the lesion still present

›Sensitivity is imperfect for coarctation of the aorta and for some mixing lesions with adequate saturations at the time of screening

›Screening performed before ductal closure may miss a lesion that becomes symptomatic days later

›A passed screen does not override clinical suspicion in a symptomatic infant

MRI

›Cardiac MRI role

›Not a first-line or emergency-department investigation

›Length of study and monitoring limitations in an unstable neonate

›MCS or ventilator incompatibility in the acutely decompensated infant

›Reserved for post-stabilization anatomic clarification

›Complex arch anatomy or collateral vessel delineation before surgical planning

›CT angiography role

›Not first-line; echocardiography is faster, radiation-free, and answers the immediate question

›Considered when arch or vascular anatomy is inadequately defined by echocardiography

›Contrast and radiation exposure are relative concerns in a neonate

›Reserve for surgical planning after initial stabilization

Ultrasound

›Echocardiography (definitive test)

›Emergent bedside or formal echocardiography for any suspected ductal-dependent lesion

›Confirms anatomic diagnosis and ductal patency

›Should never delay empiric PGE1 initiation

›Key findings by group

07Disposition/dispo24

Immediate disposition

›All confirmed or suspected ductal-dependent CHD requires ICU-level care

›Neonatal or pediatric cardiac ICU preferred

›Continuous PGE1 infusion, cardiorespiratory monitoring, and pre/post-ductal saturation monitoring throughout

›Never an observation-level diagnosis

Transfer to a pediatric cardiac center

›Transfer indications

›Any confirmed or strongly suspected ductal-dependent lesion at a center without pediatric cardiac surgery

›Do not delay transfer arrangements while awaiting definitive echocardiographic confirmation if clinical suspicion is high

›Pre-transport stabilization

›PGE1 infusion running on a secure, reliable line before departure

›Elective intubation before transport for infants on higher-dose PGE1, with apnea risk, or for prolonged transport time

›Umbilical or other reliable central access if feasible before departure

›Glucose checked and corrected before departure

›Retrieval team and transport considerations

›Specialized neonatal or pediatric cardiac transport team when available

›Backup PGE1 infusion and pump battery life confirmed for the full transport duration

›Continuous pre- and post-ductal SpO2 monitoring during transport

›Blended oxygen source available to avoid inadvertent hyperoxia en route

›Communication with the receiving cardiac center and cardiac surgery before arrival

Specialist consultation triggers

›Pediatric cardiology

›Emergent consultation on suspicion, not after confirmation

›Pediatric cardiac surgery

›Notified for any confirmed ductal-dependent lesion requiring surgical or catheter-based palliation

›Neonatology or pediatric critical care

›Co-management for airway, glucose, sepsis workup, and ongoing resuscitation

08Treatment/t123

Prostaglandin E1 (ductal patency) therapy

›Alprostadil infusion protocol

›Start 0.05-0.1 mcg/kg/min IV continuous infusion on suspicion

›Verify against current pediatric guideline before use

›Wean to lowest effective maintenance dose once ductal patency and improved perfusion are established, commonly 0.01-0.05 mcg/kg/min

›Verify against current pediatric guideline before use

›Do not exceed 0.4 mcg/kg/min; higher doses increase apnea, fever, and hypotension without added ductal effect

›Verify against current pediatric guideline before use

›Deceleration and safety qualifiers travel with the dose

›Do not interrupt the infusion for any reason without an immediate replacement running

›If the infusion must be stopped (line failure), have a second access point ready before disconnecting

›Monitoring cadence during infusion

›Continuous cardiorespiratory monitoring and continuous pulse oximetry from the first dose

›Pre- and post-ductal SpO2 recheck at least every 1-2 hours until stable, then per unit protocol

›Temperature monitoring (drug-induced fever is common and can be mistaken for sepsis progression)

›Vital signs and perfusion reassessment within 15-30 minutes of any dose change

Therapy-not-working troubleshooting

›If no improvement in saturation or perfusion after PGE1 initiation

›Confirm the infusion line is patent and actually infusing

›Infiltrated or occluded IV access is the most common cause of apparent PGE1 failure

›Confirm the dose is within the therapeutic range and has had adequate time (15-30 minutes) to act

›Reconsider a mixing lesion with a restrictive atrial septum

›Ductal patency alone may be insufficient if intracardiac mixing is inadequate

›Emergent balloon atrial septostomy may be required regardless of ductal status

›Reconsider that the ductus may already be anatomically closed

›Escalate immediately to cardiac surgery or interventional cardiology for emergent intervention

Airway, sedation, and oxygen principles

›Airway and intubation

›Anticipate PGE1-associated apnea and secure the airway proactively rather than reactively

›Hemodynamically neutral induction preferred

›Ketamine 1-2 mg/kg IV for induction in the hemodynamically unstable neonate

›Verify against current pediatric guideline before use

›Avoid agents that cause significant myocardial depression or vasodilation in an already duct-dependent circulation

›Avoid excessive positive end-expiratory pressure

›Elevated intrathoracic pressure can reduce pulmonary blood flow or further compromise cardiac output

›Sedation and analgesia

›Opioids and benzodiazepines both risk hypotension and respiratory depression that compound PGE1-induced apnea

›Use the lowest effective dose with airway support immediately available

›Fentanyl 1-2 mcg/kg IV slow push for procedural analgesia if needed

›Verify against current pediatric guideline before use

›Oxygen therapy

›Titrate to a permissive saturation target (75-85% in most ductal-dependent physiology) rather than to maximal oxygenation

›High-concentration oxygen promotes ductal closure and, in parallel-circulation lesions, redirects flow toward the lungs at the expense of the systemic circulation

›This applies to both ductal-dependent pulmonary flow and systemic flow physiology, though the mechanism of harm differs

›Use blended, titrated oxygen rather than empiric high-flow or 100% FiO2

›Reserve higher FiO2 for confirmed non-cardiac hypoxic respiratory failure once cardiac disease has been evaluated

Fluid management principles

›Cautious, reassessed fluid administration

›Small aliquots (5-10 mL/kg) with reassessment preferred over a standard 20 mL/kg bolus in suspected ductal-dependent CHD

›Verify against current pediatric guideline before use

›Aggressive fluid loading can worsen a left-sided obstructive lesion

›Increases preload against an already obstructed or hypoplastic left heart

›Worsens pulmonary venous congestion and pulmonary edema rather than improving forward flow

›Reassess perfusion, work of breathing, and lung exam after every fluid aliquot before giving more

›When volume is still appropriate

›Clear evidence of intravascular depletion (dehydration, hemorrhage) alongside the cardiac picture

›Give cautiously and reassess frequently rather than withholding entirely

Sepsis mimic: concurrent empiric treatment

›Treat both processes simultaneously rather than sequentially

›Differentiating ductal-dependent shock from neonatal sepsis by clinical exam alone is unreliable and slow

›Delaying antibiotics to confirm a cardiac cause risks mortality from untreated sepsis

›Delaying PGE1 to confirm sepsis risks mortality from ductal closure

›Obtain cultures, start antibiotics, and start PGE1 together pending results

›Empiric neonatal antibiotic regimen

›Ampicillin plus an aminoglycoside or third-generation cephalosporin, not ampicillin alone

›Ampicillin monotherapy is inadequate for gram-negative and Listeria coverage at this age

›Ampicillin 50 mg/kg IV every 8-12 hours depending on postnatal age

›Verify against current pediatric guideline before use

›Gentamicin 4-5 mg/kg IV every 24-48 hours depending on postnatal and gestational age

›Verify against current pediatric guideline before use

›If a third-generation cephalosporin is preferred, use cefotaxime rather than ceftriaxone in neonates

›Ceftriaxone displaces bilirubin from albumin and risks kernicterus, and precipitates with calcium-containing IV fluids

Vasopressor and inotrope support

›Choice of agent matters for circulation balance

›Pure vasoconstrictors can worsen systemic perfusion in parallel-circulation physiology

›Raising systemic vascular resistance increases resistance to the already compromised systemic pathway

›Milrinone or dobutamine preferred to support contractility without a dominant increase in systemic vascular resistance

›Milrinone 0.25-0.75 mcg/kg/min IV infusion, no loading bolus in the hemodynamically unstable neonate

›Verify against current pediatric guideline before use

›Use cautiously; may worsen hypotension, monitor blood pressure closely during titration

›Dobutamine 2-10 mcg/kg/min IV infusion, titrate to perfusion and blood pressure

›Verify against current pediatric guideline before use

›Epinephrine 0.05-0.3 mcg/kg/min IV infusion for refractory shock

›Verify against current pediatric guideline before use

›Reserve for refractory shock; monitor for worsening lactate and tachyarrhythmia

›Titration and monitoring cadence

›Reassess perfusion, blood pressure, and lactate every 15-30 minutes during active titration

›Wean as hemodynamics allow; avoid prolonged high-dose catecholamine exposure

Group-specific therapy: ductal-dependent pulmonary blood flow

›Cyanotic group management

›PGE1 as above to restore pulmonary blood flow via the ductus

›Avoid hyperoxia; it does not meaningfully raise saturation in a fixed right-to-left shunt and accelerates ductal closure

›Hypercyanotic spell management if applicable (severe tetralogy physiology)

›Knee-to-chest positioning, calming measures

›Morphine 0.1 mg/kg IV or SC for spell termination

›Verify against current pediatric guideline before use

›Phenylephrine 5-20 mcg/kg IV bolus to raise systemic vascular resistance and improve right-to-left shunt physiology in this specific lesion

›Verify against current pediatric guideline before use

›This is the one setting where increasing systemic vascular resistance helps, because it favors flow across the outflow obstruction toward the lungs; it does not apply to duct-dependent systemic flow lesions

Group-specific therapy: ductal-dependent systemic blood flow

›Systemic flow (shock) group management

›PGE1 as above to restore systemic perfusion via the ductus

›Avoid excess afterload reduction and excess fluid, both of which worsen a fixed left-sided obstruction

›Balance pulmonary and systemic flow (single-ventricle physiology, hypoplastic left heart syndrome)

›Avoid hyperventilation and hyperoxia, both of which lower pulmonary vascular resistance and steal flow from the systemic circulation

›Permissive hypercapnia and permissive hypoxemia are the intended strategy, not a complication to correct

Iatrogenic harms of routine ED interventions

›Intubation

›Requires modification: hemodynamically neutral induction, avoid excess PEEP; do not withhold when clinically indicated for apnea or airway protection

›Sedation and analgesia

›Requires modification: lowest effective dose, airway support ready, compounds PGE1-induced apnea

›Fluid loading

›Requires modification: small aliquots with reassessment; standard 20 mL/kg boluses can worsen left-sided obstructive physiology

›Oxygen

›Requires modification: titrate to permissive saturation target; empiric high-concentration oxygen promotes ductal closure and worsens systemic perfusion in parallel-circulation lesions

›Vasopressors

›Requires modification: pure alpha-agonists can worsen systemic perfusion in parallel-circulation physiology; inotrope-forward strategy (milrinone, dobutamine) generally preferred outside the specific hypercyanotic-spell exception

›Mechanical circulatory support, including intra-aortic balloon pump

›Contraindicated: intra-aortic balloon pump is not used in neonates; anatomy, size, and duct-dependent physiology are not compatible with balloon counterpulsation

›ECMO reserved as a bridge to surgical or catheter-based repair in refractory shock or arrest, not as a routine intervention

›Anticoagulation

›Requires modification: not routine; reserve for planned catheterization, ECMO, or surgical shunt, and weigh against intraventricular hemorrhage risk in a sick neonate

›Fibrinolysis

›Contraindicated as a routine measure: no role in ductal-dependent CHD presentation absent a separate proven thromboembolic event

›Analgesia

›Requires modification: opioids risk hypotension and respiratory depression on top of PGE1 effects; use lowest effective dose with monitoring

ECG surveillance for therapy-induced electrolyte shifts

›Diuretic-associated hypokalemia

›If loop diuretics are used for pulmonary edema or congestion, monitor for flattened T waves, U waves, and arrhythmia risk

›Acidosis-associated hyperkalemia

›In severe shock or metabolic acidosis, monitor for peaked T waves and widened QRS

›Baseline rhythm assessment

›12-lead ECG on presentation to identify arrhythmia as a contributing or alternative cause of shock

09Special Populations/sp27

Pregnancy

›Prenatal detection and delivery planning

›Fetal echocardiography for known risk factors (maternal diabetes, family history, abnormal anatomy scan)

›A prenatally diagnosed ductal-dependent lesion allows planned delivery at a center with pediatric cardiology and cardiac surgery

›Maternal counseling on delivery location and immediate postnatal PGE1 availability

›Recurrence risk counseling

›Increased recurrence risk in a subsequent pregnancy when a prior child or parent has congenital heart disease

Geriatric

›Applicability

›Not applicable

›Ductal-dependent congenital heart disease is a neonatal-specific condition tied to the physiologic closure window of the ductus arteriosus

›No geriatric-specific modifications

›Systems note

›Ensure neonatal and pediatric cardiac pathways are selected in order sets

›Avoid applying adult shock or ACS protocols to this presentation

Pediatrics

›Gestational and postnatal age considerations

›Term versus preterm neonates

›Preterm infants have higher baseline apnea risk, compounding PGE1-associated apnea

›Weight-based dosing must use actual weight; verify against current pediatric guideline before use for every dose in this file

›Timing of presentation

›Most common day 3 to day 14 of life as the ductus closes

›Later presentation to 4-6 weeks possible with a slow-closing or restrictive ductus

›Weight-based dosing verification

›Every neonatal resuscitation dose in this file (PGE1, dextrose, ketamine, fentanyl, milrinone, dobutamine, epinephrine, phenylephrine, morphine, gentamicin, ampicillin) carries an explicit verification flag

›Verify against current pediatric guideline before use

›Model and clinician recall of pediatric resuscitation doses is unreliable; confirm against a current pediatric drug reference or pharmacy at the bedside

›Family and psychosocial support

10Background/b32

Epidemiology

›Incidence

›Congenital heart disease overall affects approximately 8-9 per 1000 live births

›Roughly a quarter of these are critical, duct-dependent lesions requiring intervention in the first year of life

›Ductal-dependent pulmonary flow lesions (pulmonary atresia, critical pulmonic stenosis, tricuspid atresia) collectively account for a substantial minority of critical CHD, on the order of 10-15%

›Ductal-dependent systemic flow lesions

›Hypoplastic left heart syndrome occurs in roughly 2-3 per 10,000 live births

›Coarctation of the aorta occurs in roughly 3-4 per 10,000 live births

›Mortality without intervention

›Untreated critical ductal-dependent CHD carries mortality approaching 90% within the first weeks to months of life as the ductus closes

›Contemporary surgical and catheter-based survival for most lesions now exceeds 80-90% with timely diagnosis and treatment

Pathophysiology

›Ductus arteriosus physiology

›Fetal shunt connecting the pulmonary artery and descending aorta, patent in utero due to low oxygen tension and circulating prostaglandins

›Functional closure typically within the first 24-72 hours of life in a structurally normal heart, driven by rising oxygen tension and falling prostaglandin levels

›In ductal-dependent lesions, closure of the ductus removes the only pathway for adequate pulmonary or systemic blood flow

›Ductal-dependent pulmonary blood flow group

›Right-sided obstruction or atresia prevents antegrade flow to the lungs

›The ductus supplies retrograde flow from the aorta to the pulmonary arteries

›Transposition physiology depends on the ductus (and any other communication) for mixing of parallel circulations rather than for pulmonary flow itself

›Ductal-dependent systemic blood flow group

›Left-sided obstruction or hypoplasia prevents adequate antegrade flow to the body

›The ductus supplies retrograde flow from the pulmonary artery to the descending aorta, perfusing the lower body and, in hypoplastic left heart syndrome, the entire systemic circulation

›Balance between pulmonary and systemic vascular resistance determines the split of combined ventricular output between the two circuits in single-ventricle physiology

Therapeutic Considerations

›Rationale for PGE1 as first-line therapy

›Directly reopens or maintains ductal patency, restoring the missing flow pathway regardless of the specific anatomic lesion

›Started empirically because the mortality cost of withholding it while awaiting confirmation exceeds the cost of treating a false positive

11Patient Discharge Instructions/pdi17

copy discharge instructions

›This condition is not managed as an ED discharge

›Every infant with confirmed or strongly suspected ductal-dependent congenital heart disease is admitted or transferred; there is no outpatient pathway from this presentation

›Instructions for families after transfer or admission

›Expect a prolonged hospital stay including cardiac catheterization or surgery

›A member of the cardiology and surgical team will explain the specific lesion and planned procedure

›Ask about feeding plans, since many infants require modified feeding schedules before and after surgery

›Return to emergency immediately if a previously stable infant develops

›Increasing blue or grey color

›Poor feeding or refusal to feed

›Breathing faster than 60 breaths per minute or increased work of breathing

›Temperature above 38.0 degrees Celsius or below 36.0 degrees Celsius

›Decreased wet diapers (fewer than 4-6 in 24 hours)

›Unusual sleepiness or difficulty waking

›Discharge medication safety after any ED analgesic or antipyretic use before transfer

›Acetaminophen 10-15 mg/kg PO or PR every 4-6 hours as needed, maximum 5 doses in 24 hours

›Verify against current pediatric guideline before use

›Avoid ibuprofen and other NSAIDs in infants under 6 months and in any infant with a still-patent or recently instrumented ductus

12References/r12

Guidelines and key sources

›American Heart Association and American Academy of Pediatrics newborn pulse oximetry screening algorithm

›Endorsed screening protocol for critical congenital heart disease

›American College of Cardiology and American Heart Association guideline for the management of adults with congenital heart disease (background reference for lesion definitions)

›American Academy of Pediatrics Red Book, current edition

›Empiric neonatal sepsis antibiotic regimens and dosing bands by postnatal age

›Alprostadil (prostaglandin E1) manufacturer prescribing information

›Dosing range, apnea incidence, and adverse effect profile

Key reviews and reference texts

›Park's Pediatric Cardiology for Practitioners, current edition

›Standard reference for ductal-dependent lesion classification and initial management

›Nelson Textbook of Pediatrics, congenital heart disease chapter, current edition

›Pediatric Advanced Life Support and Neonatal Resuscitation Program materials, current edition

›Weight-based resuscitation dosing framework referenced throughout this file

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed September 13, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.